Effect of primaquine dose on the risk of recurrence in patients with uncomplicated Plasmodium vivax: a systematic review and individual patient data meta-analysis.
Commons RJ, Rajasekhar M, Edler P, Abreha T, Awab GR, Baird JK, Barber BE, Chu CS, Cui L, Daher A, Gonzalez-Ceron L, Grigg MJ, Hwang J, Karunajeewa H, Lacerda MVG, Ladeia-Andrade S, Lidia K, Llanos-Cuentas A, Longley RJ, Pereira DB, Pasaribu AP, Pukrittayakamee S, Rijal KR, Sutanto I, Taylor WRJ, Thanh PV, Thriemer K, Vieira JLF, Watson JA, Zuluaga-Idarraga LM, White NJ, Guerin PJ, Simpson JA, Price RN; WorldWide Antimalarial Resistance Network (WWARN) Vivax Primaquine Dosing Efficacy, Tolerability and Safety Study Group.
Commons RJ, et al.
Lancet Infect Dis. 2024 Feb;24(2):172-183. doi: 10.1016/S1473-3099(23)00430-9. Epub 2023 Sep 22.
Lancet Infect Dis. 2024.
PMID: 37748496
Free PMC article.